Annalise.ai Debuts Radiology Triage Suite for Chest X-Rays, Head CTs

Annalise.ai has launched Annalise Triage, a solution tailored specifically for the U.S. market. This software is likely to transform the radiology field by empowering radiologists to efficiently triage studies and prioritize those with suspected critical findings, ultimately streamlining their workflow, and supporting faster time-to-diagnosis for urgent conditions, according to the company. Artificial intelligence (AI)-enhanced worklist triaging has been shown to decrease both the time a radiologist needs to read a report, and the time from request until a report is available for critical cases.¹ 
 
Annalise Triage boasts an array of 12 U.S. Food and Drug Administration (FDA)-cleared findings, including five for chest X-ray (CXR) and seven for non-contrast head computed tomography (CT). Readily available for use throughout the United States, this offering received 510(k) clearance and breakthrough designation for obstructive hydrocephalus. Notably, Annalise Triage is the only radiology triage device to have received this distinction, which is exclusively granted to devices and products that fulfil specific criteria, which include enhancing the diagnosis or treatment of life-threatening or irreversibly debilitating conditions, offering breakthrough technology, presenting a significant advantage over existing alternatives, and being in the best interest of patients.²
 
By implementing Annalise Triage, radiologists can swiftly and accurately detect a range of critical, time-sensitive conditions from unenhanced head CT studies, including acute subdural hematoma, acute subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, obstructive hydrocephalus, mass effect, and vasogenic edema. Furthermore, it enables identification of pleural effusion, pneumoperitoneum, vertebral compression fracture, pneumothorax, and tension pneumothorax on chest X-rays. With this list of 12 time-sensitive and critical findings, Annalise Triage is the a comprehensive AI triage tool for CXR and non-contrast CTB available in the United States. 
 
In light of growing imaging backlogs and radiology workforce shortages, Annalise Triage is strategically positioned to address the pressing need to improve workflow efficiency in U.S. radiology. Annalise.ai recognized the current industry challenges and expedited regulatory approvals to be one of the fastest AI providers to achieve 12 findings cleared by FDA in less than two years. 
 
“Our advanced algorithms support radiologists by facilitating prioritization of studies with suspected critical findings, thereby optimizing radiology workflow. With its set of clearances, Annalise.ai promotes faster report turnaround times by identifying and elevating critical cases for immediate attention,” Annalise.ai Chief Medical Officer Dr. Rick Abramson said.   
 
One of Annalise’s key strengths in the U.S. radiology triage market is the breadth and depth of its triage findings. Annalise.ai algorithms are powered by one of the world’s largest, most diverse datasets and trained using a pool of more than 140 fully qualified consulting radiologists. 

With accelerating advances in medical imaging technology, radiologists and other healthcare providers are now expected to diagnose patients quickly and accurately. Annalise.ai fuses the highest quality imaging data with the very best in computer science to produce comprehensive AI clinical decision support solutions, empowering clinicians to make accurate, faster decisions. The company’s patient-first approach is clinician-led and comes from an understanding of the challenges faced in medical imaging. AI provides clinicians with a second set of eyes, allowing them to detect and protect with confidence and drive better health outcomes for all patients.

References 
¹ Karunasena S et al., 2022 
² Breakthrough Devices Program | FDA